The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The challenges and factors to consider when selecting between CAR-T products for DLBCL
In this video, Leyre Bento De Miguel, MD, Son Espases University Hospital, Palma de Mallorca, Spain, discusses the challenges and factors to consider when selecting between CAR T-cell products for patients with diffuse large B-cell lymphoma (DLBCL), highlighting the importance of taking into account both the efficacy and safety profile of different products. Dr Bento De Miguel emphasizes the need to individualize treatment strategies and select the most suitable product for each patient based on their unique characteristics. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that we have so many challenges. I mean, one of these is, I mean, efficacy. We have seen that the different products, liso-cel and axi-cel, have the same efficacy. So this is a really good point. So we have more than one product that we can use, but we have a really important challenge that is, for example, the safety profile. So it’s not only to have an efficacious product, but also safety is really important...
I think that we have so many challenges. I mean, one of these is, I mean, efficacy. We have seen that the different products, liso-cel and axi-cel, have the same efficacy. So this is a really good point. So we have more than one product that we can use, but we have a really important challenge that is, for example, the safety profile. So it’s not only to have an efficacious product, but also safety is really important. If we have a patient that is maybe an elderly patient or has an ECOG that is on the limit or maybe some comorbidities, so maybe the safety profile could be a challenge for us. Also, we can have a really aggressive disease. So for example, the time will be a really key point. So maybe the vein-to-vein time will be critical. And in this situation, for example, axi-cel has the shortest vein-to-vein time. So maybe it could be a really good option for patients with a very aggressive disease. So I think that we need to individualize each strategy and we need to learn about each patient and see which product could be the best option for him or for her.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
